Minaris Restructures With Dedicated Viral Vector Unit Amid Market Shifts

PHILADELPHIA, PA – September 29, 2026 – In a move that highlights the widening technological divide between traditional cell therapies and next-generation gene delivery, Minaris Advanced Therapies has announced a sweeping reorganization of its operational model. Effective October 1, the global contract development and manufacturing organization (CDMO) will split its operations into three distinct business units: Minaris Cell Therapies, Minaris Viral Vectors, and Minaris Advanced Testing.

The restructuring represents far more than a simple corporate reshuffling. It is a calculated response to a persistent capacity crunch in the biopharmaceutical supply chain and a strategic pivot toward the booming in vivo gene therapy market. By isolating viral vector manufacturing into its own dedicated division, the company is acknowledging that the production of advanced delivery mechanisms like Adeno-Associated Virus (AAV) and lentivirus requires specialized infrastructure fundamentally different from traditional cell processing.

The Post-WuXi Transformation and Geopolitical Neutrality

To understand the significance of this reorganization, one must look at the foundation of Minaris Advanced Therapies. The company in its current form was forged in 2025 through a series of acquisitions by New York-based private equity firm Altaris. By purchasing Minaris Regenerative Medicine from Resonac Holdings Corporation and merging it with the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies Unit, Altaris created a global CDMO powerhouse boasting over 1,400 employees and 730,000 square feet of infrastructure.

The acquisition of the WuXi assets was heavily influenced by shifting geopolitical tides. Throughout 2024 and 2025, the looming threat of the BIOSECURE Act—legislation designed to prohibit U.S. federal funding for companies working with certain Chinese biotechnology providers—sent shockwaves through the industry supply chain. The act, eventually signed into law in December 2025, forced a rapid "de-China'ing" of critical biomanufacturing assets.

By absorbing the WuXi facilities into an American-owned entity, Altaris effectively granted these operations geopolitical neutrality. Today, the newly structured CDMO operates free from BIOSECURE restrictions, offering Western biopharma companies a secure, compliant harbor for their most sensitive manufacturing processes. This geopolitical positioning is a critical competitive advantage as the industry scrambles to diversify supply chains away from adversarial risks.

The In Vivo Pivot: Segregating Vectors from Cells

The decision to create a standalone Minaris Viral Vectors unit, led by newly appointed Chief Commercial and Technology Officer Dr. Eytan Abraham, underscores a profound technological divergence in modern medicine. While traditional ex vivo cell therapies require complex, patient-specific handling, the industry is rapidly expanding toward in vivo gene therapies. These treatments, which deliver genetic material directly into the patient's body, rely heavily on robust, high-yield viral vectors.

Market data illustrates the urgency of this shift. The global viral vector manufacturing market, valued at $6.7 billion in 2025, is projected to surge to $19.5 billion by 2033. In vivo therapies already account for nearly 64% of this market. Yet, despite significant capital deployment across the sector, biopharma companies are hitting a wall. Recent industry surveys indicate that nearly 56% of developers struggle to secure CDMO capacity for gene therapies, largely due to the technical complexity and high capital costs of downstream purification.

"Minaris is entering its next phase with a business model that reflects both the evolving needs of our customers and the direction of the markets we serve," said Orla Cloak, Chief Executive Officer at Minaris. "The addition of a dedicated Viral Vectors business unit allows us to bring greater focus to an area that is increasingly important to cell and gene therapy developers, while continuing to build on our established strengths in cell therapies and advanced testing."

Fortifying 'Cellicon Valley' with Next-Gen Tech

The physical heart of this new viral vector push is centralized in Philadelphia, a region affectionately dubbed "Cellicon Valley" for its dense concentration of advanced therapy infrastructure. The company's Navy Yard campus houses a 150,000 square-foot manufacturing facility capable of up to 2,000-liter scale production utilizing single-use technologies.

However, the true differentiator for the new Viral Vectors unit lies across the Atlantic. Through the WuXi acquisition, the CDMO inherited Oxford-based OXGENE, a center of excellence for advanced viral vector technology. The integration of OXGENE's proprietary platforms into the Philadelphia manufacturing base is designed to solve the industry's most pressing yield and scalability issues.

Key among these technologies is the TESSA AAV production system, a plasmid-free platform that can reportedly increase yields up to 30-fold compared to traditional methods while reducing impurities. Additionally, the XOFLX lentiviral technology utilizes stable packaging and producer cell lines to overcome the limitations of transient transfection, allowing for highly reproducible, 1,000-liter-plus production runs. Recent strategic partnerships with firms like Asimov and Bionova Scientific further indicate that the company is aggressively monetizing these proprietary plasmid and cell-line technologies to capture a larger share of the AAV and lentiviral markets.

Leadership for a Fragmented Supply Chain

Executing a tripartite operational model requires rigorous leadership, and the company has tapped veterans of the biopharmaceutical space to head its distinct units. Dr. Luciana Mansolelli, bringing nearly three decades of experience from Johnson & Johnson and Novartis, will lead Minaris Cell Therapies. Her background in both sponsor and CDMO quality systems will be critical as the unit continues to support autologous and allogeneic programs across the U.S., Europe, and Asia.

Dr. Eytan Abraham, taking the helm of the Viral Vectors unit, brings a deep background in advanced modalities from tenures at National Resilience and Lonza. His mandate will be to seamlessly merge the OXGENE technological platforms with the Philadelphia-based commercial manufacturing footprint.

Rounding out the trio is Dr. Ilya Koltover, who will direct Minaris Advanced Testing. With an extensive background managing contract testing laboratories for Solvias and MilliporeSigma, he oversees a 140,000 square-foot dedicated testing facility in Philadelphia. This unit, which recently expanded its viral clearance lab capacity by 25%, provides the essential biosafety, potency, and analytical testing required to move complex therapies through stringent regulatory pathways.

By unbundling its services into three highly specialized units, the organization is acknowledging that the era of the generalist CDMO is coming to an end. As advanced therapies become increasingly complex, developers require partners who can offer both the deep, specific technical expertise of a boutique firm and the scalable, geopolitically secure infrastructure of a global enterprise. The new operational structure goes into effect at the start of the fourth quarter, setting a new baseline for how contract manufacturers align their internal operations with the cutting edge of genomic medicine.